Additionally, one or more compounds of the present invention can be co-administered or used in combination with one or more disease-modifying antirheumatic drugs (DMARDS) such as methotrexate, azathioprine leflunomide, penicillamine, gold salts, mycophenolate mofetil, cyclophosphamide and other similar drugs. One or more compounds of the invention can also be co-administered with or used in combination with one or more NSAIDS such as piroxicam, naproxen, indomethacin, ibuprofen and the like; one or more COX-2 selective inhibitors such as Vioxx® (rofecoxib from Merck & Company, Whitehouse Station, NJ) and Celebrex® (celecoxib from Pfizer Inc., New York, New York); one or more COX-1 inhibitors such as Feldene® (Piroxicam from Pfizer Inc., New York, New York); immunosuppressives such as steroids, cyclosporine, Tacrolimus, rapamycin, muromonab-CD3 (OKT3), Basiliximab and the like; biological response modifiers (BRMs) such as Enbrel® (etanercept from Wyeth-Ayerst, Philadelphia, PA), Remicade® (infliximab from Centocor, Inc., Malvern, PA), IL-1 antagonists, anti-CD40, anti-CD28, IL-10, anti-adhesion molecules and the like; and other anti-inflammatory agents such as p38 kinase inhibitors, PDE4 inhibitors, TACE inhibitors, chemokine receptor antagonists, Thalidomide® (Celgene Corporation, Warren, NJ) and/or other small molecule inhibitors of pro-inflammatory cytokine production. One or more compounds of this invention can also be co-administered with or used in combination with one or more H1 antagonists such as Claritin® (loratadine from Schering-Plough Corporation, Kenilworth, NJ), Clarinex® (desloratadine from Schering-Plough Corporation, Kenilworth, NJ), Zyrtec® (cetirizine HCl from Pfizer Inc., New York, New York), Allegra® (fexofenadine from Aventis, Bridgewater, NJ), Benadryl® (diphenhydramine from Parke-Davis, Morris Plains, NJ), and other H1 antagonists. Other drugs that the compounds of the invention can be co-administered or used in combination with include Anaprox, Arava, Arthrotec, Azulfidine, Aspirin, Cataflam, Celestone Soluspan, Clinoril, Cortone Acetate, Cuprimine, Daypro, Decadron, Depen, Depo-Medrol, Disalcid, Dolobid, Naprosyn, Gengraf, Hydrocortone, Imuran, Indocin, Lodine, Motrin, Myochrysine,

Nalfon, Naprelan, Neoral, Orudis, Oruvail, Pediapred, Plaquenil, Prelone, Relafen, Solu-Medrol, Tolectin, Trilisate and/or Volataren. These include any formulations of the above-named drugs.

For the treatment of multiple sclerosis, one or more compounds of the invention can be co-administered or used in combination with Avonex® (interferon beta-1a from Biogen, Cambridge, MA), Betaseron® (Interferon beta-1b from Chiron from Emeryville, CA) and/or Copaxone® (glatiramer acetate from Teva Pharmaceutical Industries, North Wales, PA).

IN THE CLAIMS

Please cancel claims 20 and 23-27 without prejudice.

Please cancel claims 6 without prejudice and substitute cancelled claim 6 with new claim 58 therefor.

--58. (New) The compound according to Claim 1 of the formula



or a pharmaceutically acceptable salt or solvate thereof, wherein X and R^4 are as shown in the table below:

Example	X	R^4
A	OCH_3	
B	OCH_3